Access to novel anti-diabetic agents in resource limited settings: A brief commentary.
World J Diabetes
; 14(7): 939-941, 2023 Jul 15.
Article
en En
| MEDLINE
| ID: mdl-37547585
The prevalence of diabetes mellitus is increasing in resource limited settings. Simultaneously, there has been an increase in the number of novel therapies for the management of diabetes mellitus. However, use of novel antidiabetic therapies is limited because of major market access challenges in resource limited settings. Niching products to those patients with the highest absolute risk for major adverse cardiovascular outcomes, and thus most likely to benefit from the therapy, are less likely to have negative budget impact for funders. To improve access, and reduce morbidity and mortality, requires alignment amongst key stakeholders including patient advocacy groups, health care professional councils, national departments of health, the pharmaceutical industry, treasury and finance departments.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Tipo de estudio:
Risk_factors_studies
Idioma:
En
Revista:
World J Diabetes
Año:
2023
Tipo del documento:
Article
País de afiliación:
Sudáfrica
Pais de publicación:
Estados Unidos